Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer.
This retrospective, observational study evaluated the initial use of the first FDA-approved biosimilar to bevacizumab, bevacizumab-awwb, across its approved indications in real-world US community and academic oncology practices. The findings of the study were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
This study utilized structured patient-level data from the electronic health record–derived Oncology Services Comprehensive Electronic Records database, which includes >2.2 million US patients with cancer from >280 cancer clinics. Inclusion criteria for this analysis were adult patients who received ≥1 bevacizumab-awwb infusions between July 30, 2019, and April 30, 2020.
A total of 2422 patients were treated with bevacizumab-awwb and included all approved cancer indications. Biosimilar uptake was most prevalent in metastatic colorectal cancer (68%), followed by non–small-cell lung cancer (14%), brain cancer (11%), cervical cancer (5%), and metastatic renal-cell carcinoma (1%). Among 1657 patients with metastatic colorectal cancer who were administered bevacizumab-awwb, 59% had prior bevacizumab reference exposure; of these, 67% received bevacizumab-awwb within 28 days of the last infusion of the reference product. Baseline and clinical characteristics were comparable between the patient cohorts with and without prior bevacizumab exposure.
Based on these results, the authors concluded that physicians are comfortable initiating or transitioning patients to bevacizumab-awwb across its indications.
Source: Jin R, Accortt NA, Sandschafer D, et al. Initial experience of patients treated in a real-world clinical setting with bevacizumab-awwb: the first FDA-approved biosimilar to bevacizumab. J Clin Oncol. 2021;39(suppl_3):81-81.
